Protein therapeutics: Promises and challenges for the 21st century

Trends in Biotechnology

Volumn 20, Issue 1, 2002, Pages 29-35

  Weng, Zhiping ^a   DeLisi, Charles ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; COMPUTATIONAL METHODS; DISEASES; DNA; DRUG DOSAGE; TOXICITY;

DRUG CANDIDATES;

PROTEINS;

COMPLEMENTARY DNA; DNA; MESSENGER RNA;

BIOTECHNOLOGY;

DNA MICROARRAY; DNA PROBE; DRUG MANUFACTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; MASS SPECTROMETRY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; REVIEW; TECHNOLOGY; TOXICITY; TWO HYBRID SYSTEM; YEAST;

ANIMALS; BIOMEDICAL ENHANCEMENT; DRUG DESIGN; FORECASTING; GENE EXPRESSION PROFILING; HUMANS; LIGANDS; MASS SPECTROMETRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THERAPEUTICS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 0036139210     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(01)01846-7     Document Type: Review

References (104)

1. Expression profiling using cDNA microarrays
2. High density synthetic oligonucleotide arrays
3. Printing proteins as microarrays for high-throughput function determination
4. Proteomics on a chip
5. Variation is the spice of life
6. Computational biology. Bioinformatics - Trying to swim in a sea of data
7. The integration of microarray information in the drug development process
8. DNA microarrays in drug discovery and development
9. Microarrays and toxicology: The advent of toxicogenomics
10. Soft drug design: General principles and recent applications
11. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing
12. Drug screening - Beyond the bottleneck
13. Light-directed, spatially addressable parallel chemical synthesis
14. Microarrays: Biotechnology's discovery platform for functional genomics
15. Discovering novel chemotherapeutic drugs for the third millennium
16. High throughput gene expression screening: Its emerging role in drug discovery
17. Use of a cDNA microarray to analyse gene expression patterns in human cancer
18. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
19. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
20. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays
21. Gene-expression profiles in hereditary breast cancer
22. Identification by cDNA microarray of genes involved in ovarian carcinogenesis
23. Tobacco smoke carcinogens and lung cancer
24. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages
25. The impact of Genomics' technologies on pharmaceutical research
26. Genetics, genomics, and drug discovery
27. Proteomics to study genes and genomes
28. Protein arrays and microarrays
29. Protein biochips for differential profiling
30. Post-translational modification of proteins and the discovery of new medicine
31. Use of mass spectrometry-derived data to annotate nucleotide and protein sequence databases
32. Database searching using mass spectrometry data
33. The yeast nuclear pore complex: Composition, architecture, and transport mechanism
34. Proteomics of the chloroplast: Systematic identification and targeting analysis of lumenal and peripheral thylakoid proteins
35. Identification of the proteins of the yeast U1 small nuclear ribonucleoprotein complex by mass spectrometry
36. The protein-protein interaction map of Helicobacter pylori
37. Protein interaction mapping in C. elegans using proteins involved in vulval development
38. Toward a protein-protein interaction map of the budding yeast: A comprehensive system to examine two-hybrid interactions in all possible combinations between the yeast proteins
39. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae
40. Display cloning: Functional identification of natural product receptors using cDNA-phage display
41. Identification of natural ligands for SH2 domains from a phage display cDNA library
42. A receptor for phosphatidylserine-specific clearance of apoptotic cells
43. Phage display of combinatorial antibody libraries
44. Phage display in pharmaceutical biotechnology
45. Selecting and evolving functional proteins in vitro by ribosome display
46. RNA-peptide fusions for the in vitro selection of peptides and proteins
47. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: A system designed for exploring protein-protein interactions
48. Yeast surface display for directed evolution of protein expression, affinity, and stability
49. Genetic selection of peptide inhibitors of biological pathways
50. Applications of display technology in protein analysis
51. Biotechnology match making: Screening orphan ligands and receptors
52. Combinatorial protein reagents to manipulate protein function
53. Combination of DMT-mononucleotide and Fmoc-trinucleotide phosphoramidites in oligonucleotide synthesis affords an automatable codon-level mutagenesis method
54. Constructing high complexity synthetic libraries of long ORFs using in vitro selection
55. Amino acid substitutions: Effects on protein stability
56. Selection of functional T cell receptor mutants from a yeast surface-display library
57. Rapid evolution of a protein in vitro by DNA shuffling
58. Genetic algorithms - Principles of natural selection applied to computation
59. Evolution of a cytokine using DNA family shuffling
60. Mini-review: Computational structure-based design of inhibitors that target protein surfaces
61. Recent advances in structure-based rational drug design
62. Specificity in structure-based drug design: Identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase
63. Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations
64. Quantifying biological specificity: The statistical mechanics of molecular recognition
65. Protein-protein docking. Generation and filtering of complexes
66. A continuum model for protein-protein interactions: Application to the docking problem
67. Hydrophobic docking: A proposed enhancement to molecular recognition techniques
68. Effect of conformational flexibility and solvation on receptor-ligand binding free energies
69. Prediction of protein complexes using empirical free energy functions
70. Computational determination of the structure of rat Fc bound to the neonatal Fc receptor
71. Determination of atomic desolvation energies from the structures of crystallized proteins
72. Consistency in structural energetics of protein folding and peptide recognition
73. Modelling protein docking using shape complementarity, electrostatics and biochemical information
74. Convergent solutions to binding at a protein-protein interface
75. X-SITE: Use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins
76. Fast prediction and visualization of protein binding pockets with PASS
77. A fast method to predict protein interaction sites from sequences
78. What makes a binding site a binding site?
79. New approaches to rational drug design
80. Molecular surface recognition: Determination of geometric fit between proteins and their ligands by correlation techniques
81. BiGGER: A new (soft) docking algorithm for predicting protein interactions
82. Protein docking using spherical polar Fourier correlations
83. Protein docking using a genetic algorithm
84. A systematic study of low-resolution recognition in protein-protein complexes
85. Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase
86. Evaluation of the CASP2 docking section
87. Rapid refinement of protein interfaces incorporating solvation: Application to the docking problem
88. Scoring docked conformations generated by rigid-body protein-protein docking
89. Structural genomics: Beyond the human genome project
90. Computational protein engineering
91. De novo design and structural characterization of proteins and metalloproteins
92. Energy functions for protein design
93. De novo protein design: Fully automated sequence selection
94. Design, structure and stability of a hyperthermophilic protein variant
95. All in one: A highly detailed rotamer library improves both accuracy and speed in the modelling of sidechains by dead-end elimination
96. Achieving stability and conformational specificity in designed proteins via binary patterning
97. Designed protein G core variants fold to native-like structures: Sequence selection by ORBIT tolerates variation in backbone specification
98. Trading accuracy for speed: A quantitative comparison of search algorithms in protein sequence design
99. Automatic protein design with all atom force-fields by exact and heuristic optimization
100. Generalized dead-end elimination algorithms make large-scale protein side-chain structure prediction tractable: Implications for protein design and structural genomics
101. Ligand recognition by alpha beta T cell receptors
102. Toward a predictive understanding of molecular recognition
103. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range
104. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display